Weiss J S, Weiss J N, Greenfield D S
Kresge Eye Institute, Detroit, Michigan 48201, USA.
Retina. 1995;15(2):130-3. doi: 10.1097/00006982-199515020-00007.
A prospective, double-blind study was conducted to compare the clinical efficacy of a combination of 1% tropicamide and 2.5% phenylephrine and a combination of 1% tropicamide and 10% phenylephrine for pupillary dilation in patients with diabetes.
Either 2.5% phenylephrine in one eye and 10% phenylephrine in the other eye, 2.5% phenylephrine in both eyes, or 10% phenylephrine in both eyes was administered to 127 consecutive patients with diabetes. All patients received 1% tropicamide in both eyes.
There was no statistically significant difference in the amount of pupillary dilation between the three groups.
As 2.5% phenylephrine may produce a lower incidence of side effects than the 10% concentration, we advise the use of the lower concentration, particularly among patients with diabetes, who already exhibit a higher prevalence of vascular disease and autonomic dysfunction.
进行一项前瞻性双盲研究,以比较1%托吡卡胺与2.5%去氧肾上腺素联合用药和1%托吡卡胺与10%去氧肾上腺素联合用药对糖尿病患者散瞳的临床疗效。
对127例连续的糖尿病患者,一只眼给予2.5%去氧肾上腺素,另一只眼给予10%去氧肾上腺素,或者双眼均给予2.5%去氧肾上腺素,或者双眼均给予10%去氧肾上腺素。所有患者双眼均接受1%托吡卡胺。
三组之间瞳孔散大程度无统计学显著差异。
由于2.5%去氧肾上腺素可能比10%浓度的药物产生更低的副作用发生率,我们建议使用较低浓度的药物,特别是在已经表现出较高血管疾病和自主神经功能障碍患病率的糖尿病患者中。